Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases.
Our most advanced program is abelacimab, an investigational monoclonal antibody that achieves profound suppression of the novel antithrombotic target Factor XI through dual activity against both Factor XI itself and its activated form, Factor XIa. Abelacimab represents a promising next-generation anticoagulant with the potential to provide ‘hemostasis-sparing anticoagulation’: vital protection from arterial and venous thromboembolic events with a reduced risk of clinically significant bleeding.
Through targeting Factor XI, our vision is to pharmacologically ‘uncouple’ pathological thrombosis from physiological hemostasis, bringing the paradigm shift of ‘hemostasis-sparing’ anticoagulation within reach.
Watch: Factor XI inhibition—uncoupling hemostasis from thrombosis
Abelacimab, with its novel dual activity against Factor XI and XIa, has the potential to turn our vision of hemostasis-sparing anticoagulation into reality.